30 closest matches · ranked by relevance
Asthma
Primary: The Primary Endpoint of the Study is the Percent of Eosinophils in the Bronchoalveolar Lavage Fluid After Segmental Allergen Challenge, Before and After Mepolizumab…
Congenital Diaphragmatic Hernia
Primary: Number of Participants With Elevated Sputum Eosinophils — 0 participants
Asthma
Primary: Difference in ASM Mass Between Groups
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
Lung Inflammation
Primary: Change in Ki (Measure of [18F]Fluorodeoxyglucose ([18F]FDG) Uptake Determined by Patlak Graphical Analysis) in the Right Lung 24 Hours After LPS Instillation — 18.8…
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
Asthma
Primary: Change in TSLP Gene Expression — 0.000197; 0.000035 Fold Change
Asthma
Primary: Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With…
Nasal Polyps · Aspirin-exacerbated Respiratory Disease
Primary: Number of Participants With Nasal Polyp Plasma Cell Transcriptome — 10; 10; 10 Participants
Asthma, Aspirin-Induced · Chronic Rhinosinusitis With Nasal Polyps
Primary: Change From Baseline at Week 16 in Sinonasal Outcome Test -22 (SNOT-22) Score — -14.09; -4.37 points
Asthma
Primary: Concentration (pg/ml) of CXCL8 Cytokine in Cell Supernatant After Stimulation (IFN/TNF or IL13) and Treatment (VR588, FP or CP) Conditions in ALI Cultured Epithelial…
Asthma · COPD · Emphysema
Primary: Total Number of Inflammatory Cells Recovered in Sputum — 2.3; 2.1; 1.9; 5.2 10^6 cells/ml — p=0.1
Asthma
Primary: Lung Function FEV1 — 84.9; 59.9 % of predicted — p=0.001
Asthma
Primary: Change From Baseline in Eosinophils Cells Count in the Bronchial Submucosa at Week 12 — 5.80; -6.04 cells/mm^2 — p=0.8400
Asthma
Primary: Fold Increase in ASM Proliferation Following Incubation With Eosinophils. — 2; 2 Fold increase in ASM cell proliferation — p=<0.05
Severe Asthma
Primary: Airway Resistance at 5 Hz (R5) at Baseline (Pre-mepolizumab Initiation) — 0.51; 0.39; 0.43 kPa/L/s
Asthma · COPD · Interstitial Lung Disease
Primary: FEV1 — 3.03; 2.32; 3.18; 2.76 L
Smoking
Primary: Airway Blood Flow — 2.13; 13.05 ΔQaw (ul/min/ml)
Asthma
Primary: Change in Forced Expiratory Volume in 1 Second (FEV1) — -24.66; -8.44; -9.15; -16.17 Percentage drop in FEV1 — p=<0.0001
COPD
Primary: Airway Blood Flow Reactivity (Delta Qaw) — 29.1; 13.7; 8.9; 15.6 % of change
Mild Persistent Asthma
Primary: Baseline Lung Function of Rrs 5 With IOS Before the Bronchodilator (Pre-Rrs5) — 0.73; 0.74; 0.73 kPa/L/s
Atopic Asthma
Primary: Baseline Percentage of Eosinophils Recovered in the BAL Prior to Segmental Allergen Challenge — 42; 19 percentage of cells
ALLERGIC ASTHMA
Primary: Number of Participants With Change in Sputum Markers by End of Study — 0; 0 Participants
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Post-bronchodilator FEV1/FVC <=70% Versus Participants With a Postbronchodilator FEV1/FVC >70% — 308; 893 participants
Asthma
Primary: Airway Blood Flow (Qaw) — 22.3; 29.4; 34.1; 28.2 percentage of change from baseline
Allergic Asthma
Primary: Change in Exhaled Nitric Oxide From Baseline to Week 12 — -11.0 parts per billion (ppb) — p=0.005
Asthma
Primary: Difference in Baseline T Cell miRNA Expression Between Asthmatics and Healthy Controls — 13.2; 10.2; 13.6; 11.7 Normalized log2 copy number — p=0.32
Allergic Asthma
Primary: Change From Baseline in Total Subepithelial Eosinophils at the End of Week 78 (End of Treatment) — -5.807; -5.890; 1.555; -5.626 cells/mm^2
Asthma
Primary: The Primary Outcome Measure for This Study is the Number of Sputum Myeloid Dendritic Cells — 32800; 89100 number of cells/g of sputum
Bronchiolitis · Respiratory Syncytial Virus Infections
Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020